Pharma News

Looking out for latest news on Pharma Magazine?
Check out the latest Pharma news, Top news in Pharma Magazine, Leading Magazine in Pharma industry. Daily news updates pertinent to the industrial sectors we are engaged with are depicted on the news section of Pharma industry which we operate.

Grünenthal and Mundipharma Enter Commercial Partnership in China

Tuesday, January 16, 2018

Grnenthal and Mundipharma announced today that they have entered into a License and Distribution Agreement Under its terms Mundipharma will market and distribute Grnenthal39s Tramal tramadol in China from May 1 2018 Developed by Grnenthal Tramal is a wellestablished analgesic for the treatment of..

Nuvo Pharmaceuticals (Ireland) Limited Acquires U.S. Product Rights to Resultz® from Piedmont Pharmaceuticals LLC

Tuesday, January 16, 2018

Nuvo Pharmaceuticals Inc a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities today announced that its wholly owned subsidiary Nuvo Pharmaceuticals Ireland Limited Nuvo Ireland has acquired the US rights to Resultz 50 isopropyl myrista..

Ligand Enters into Worldwide OmniAb® Platform License Agreement with Glenmark Pharmaceuticals

Friday, January 12, 2018

Ligand Pharmaceuticals Incorporated announces it has entered a worldwide OmniAb platform license agreement with Glenmark Pharmaceuticals Under the license Glenmark will be able to use the full OmniAb platform including OmniChicken OmniRat OmniMouse and OmniFlic to discover fully human mono and multi..

Resverlogix Receives FDA Protocol Acceptance for the Ongoing Phase 3 BETonMACE Trial

Friday, January 12, 2018

Resverlogix Corp and the Resverlogix BETonMACE Clinical Steering Committee CSC represented by Professor Kausik Ray Chair are pleased to announce the FDA acceptance of the Companys Phase 3 BETonMACE trial Protocol amendments On behalf of all members of the BETonMACE CSC Professor Kausik Ray welcom..

Adimab Announces Antibody Discovery Collaboration with Boehringer Ingelheim

Thursday, January 11, 2018

Adimab LLC the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies today announced a multitarget partnership with Boehringer Ingelheim BI Under the terms of the agreement Adimab will use its proprietary platform to discover and optimize antibodies agai..

TARGET PharmaSolutions to advance NASH Research through new collaboration

Thursday, January 11, 2018

TARGET PharmaSolutions Inc a realworld data solutions company is pleased to announce that Novartis has entered into a longterm strategic alliance for TARGETNASH TARGETNASH is a longitudinal observational study that evaluates adult and pediatric patients with nonalcoholic fatty liver disease NAFLD..

Syapse Enters Strategic Collaboration with Roche to Advance Precision Medicine in Oncology

Wednesday, January 10, 2018

Syapse a leading precision medicine company announced today it has entered into a multiyear strategic collaboration with Roche to make precision medicine a reality for more cancer patients and their healthcare providers Syapse and Roche will work jointly to develop software products and analytics..

GT Biopharma Announces Completion of Dosing in Phase 1 Clinical Trial of GTP-004 for Myasthenia Gravis

Wednesday, January 10, 2018

GT Biopharma Inc and announced that it has completed dosing in its Phase 1 clinical trial for GTP004 its promising treatment for the symptoms of myasthenia gravis The results provide evidence that GTP004 enables the safe and welltolerated administration of doses of pyridostigmine GTP004 combines ..

Intec Pharma Announces Development Collaboration With Global Pharmaceutical Company

Tuesday, January 09, 2018

Intec Pharma Ltd a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology today announced it has entered into a Feasibility and Option agreement with Novartis Pharmaceuticals to explore using the Accordion Pill platform for a ..

Mallinckrodt Will Sell RECOTHROM® And PREVELEAK® To Baxter

Tuesday, January 09, 2018

Mallinckrodt plc a leading specialty pharmaceutical company announced today it has entered into an agreement under which it will sell certain hemostasis products to Baxter International Inc NYSE BAX for approximately 185 million with upfront payment of 153 million inclusive of existing inventory and..

TOP